FT-2102
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for FT-2102, covering 2023-01-25 to 2025-06-26. Get the full timeline:
Most recent: Clinical Trial Update: Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation [Phase 1, Phase 2]